Live Demo:
This is a live DrugChatter demonstration using real AI-generated drug queries and analysis.
Want to see how your drug is represented by AI?
Contact DrugChatter
keytruda
Brand Visibility Tracking
How this brand shows up in AI chatbot answers — presence, position, sentiment, and how it stacks up against competitors.
–
Score / 100
Latest check
Weighted composite of presence, position, sentiment, and recommendation strength across tracked prompts.
Presence
–
Avg. position
–
Lower is betterSentiment
–
Recommendation mix — latest check
How the brand was framed across the latest tracked prompts.
Competitive landscape — latest check
Visibility vs. sentiment. Bubble size reflects rank position (bigger = higher-ranked).
Best known for — latest check
Comparative research including head-to-head studies
Strong positioning in MSI-H/dMMR tumors
Keytruda is an immunotherapy (a monoclonal antibody biologic).
They’re both immune checkpoint inhibitors
Core Claims — latest check
Keytruda is the brand name for pembrolizumab.
Opdivo is the brand name for nivolumab.
Pembrolizumab (Keytruda): commonly given every 3 weeks (or sometimes every 6 weeks) depending on regimen/label and the country.
Nivolumab (Opdivo): commonly given every 2 weeks or every 4 weeks depending on regimen/label and country.
KEYNOTE-067 head-to-head trial comparing Keytruda (pembrolizumab) vs Opdivo (nivolumab)
Differentiators — latest check
Keytruda and Opdivo are both PD-1–blocking monoclonal antibodies.
Differences mainly in approved indications and dosing schedules.
One may be preferred over the other depending on regimen.
Different endpoints and populations can influence outcomes
Durability vs median outcomes can affect perceived effectiveness
Competitor comparison — latest check
| Brand | Visibility | Sentiment | Position | Recommended |
|---|
30-day composite trends
Score
Overall composite score, per day.
Visibility vs. sentiment
Two lenses on the same conversations — how much the brand shows up, and how it's spoken about.
Average rank position
Where the brand lands among all brands mentioned, in reading order. Lower is better.
Recent checks
| Date | Score | Visibility | Position | Sentiment |
|---|---|---|---|---|
| Aug 14, 2026 | 66 | 68 | 1 | 55 |
| Aug 15, 2026 | 62 | 62 | 1 | 52 |
| Aug 16, 2026 | 58 | 67 | 1 | 54 |
| Aug 17, 2026 | 59 | 68 | 1 | 53 |
| Aug 18, 2026 | 66 | 68 | 1 | 50 |
| Aug 19, 2026 | 62 | 68 | 1 | 57 |
| Aug 20, 2026 | 60 | 72 | 1 | 50 |
| Aug 21, 2026 | 51 | 63 | 1 | 58 |
| Aug 22, 2026 | 56 | 65 | 0 | 50 |
| Aug 23, 2026 | 55 | 64 | 1 | 55 |
| Aug 24, 2026 | 63 | 71 | 1 | 50 |
| Aug 25, 2026 | 58 | 61 | 1 | 50 |
| Aug 26, 2026 | 60 | 71 | 1 | 54 |
| Aug 27, 2026 | 63 | 70 | 1 | 55 |
| Aug 28, 2026 | 51 | 63 | 1 | 50 |
| Aug 29, 2026 | 62 | 65 | 1 | 54 |